{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:25:33Z","timestamp":1787117133604,"version":"build-2736575974"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The use of stereotactic body radiotherapy for primary and secondary lung lesions is well established. Although being supported by international guidelines, the application of single-fraction treatments is less reported in the literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We report a mono-institutional, retrospective analysis of inoperable patients with small lung lesions\u2014including both primary tumors and oligometastases\u2014treated with single-fraction SBRT (SF-SBRT) via a helical tomotherapy linac. Although analyzed retrospectively, all data were prospectively collected. Acute and late toxicities were graded using CTCAE v5.0, while local control (LC), distant progression-free survival (DPFS), and overall survival (OS) were estimated via Kaplan\u2013Meier and Cox regression models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      From August 2023\u00a0a total of 50 lung lesions in 49 patients. median age of 77 years (IQR, 72\u201380) received SF-SBRT. Thirty patients (61.2%) were male. Seven patients (14.3%) had a pacemaker or implantable cardioverter-defibrillator. Of the 50 treated lesions, 30 (60.0%) were primary NSCLC and 20 (40.0%) were pulmonary metastases, being colorectal cancer the most frequent non-pulmonary primary tumor. Most lesions were located in the right lung (62.0%) and in the upper lobe (64.0%). The median maximum tumour diameter was 1.9\u00a0cm (IQR, 1.6\u20132.4), and median prescription dose, for the entire cohort, was 27 Gy (IQR, 26\u201328), corresponding to a median BED\n                      <jats:sub>10<\/jats:sub>\n                      of 100 Gy (IQR, 93.6\u2013106.4). At a median follow-up of 13.7 months, one local recurrence was observed among the 50 treated lesions (2.0%), distant progression occurred in six of 49 patients (12.2%), while three patients (6.1%) died during follow-up. The estimated 12-month local control, distant progression-free survival and overall survival rates were respectively 100.0%, 89.4% (95% CI, 78.7\u2013100.0%) and 89.5% (95% CI, 78.9\u2013100.0%). No grade 3 or higher adverse events were recorded for both acute and late toxicity patterns.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In elderly patients with a significant burden of comorbidities presenting with isolated lung malignancies, single-fraction SBRT achieved remarkable metabolic responses alongside excellent short-term tolerance and survival. Despite the limitations of a small sample size and few events, these findings support the feasibility and biological effectiveness of single-fraction RT in selected frail subjects, warranting further prospective validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1933254","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:41:34Z","timestamp":1787114494000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Single-fraction stereotactic radiotherapy for lung malignancies: preliminary results of a mono-institutional experience"],"prefix":"10.3389","volume":"16","author":[{"given":"Francesco","family":"Cuccia","sequence":"first","affiliation":[{"name":"Radiation Oncology, Azienda di Rilievo Nazionale ad Alta Specializzazione (ARNAS) Civico Hospital","place":["Palermo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Mortellaro","sequence":"additional","affiliation":[{"name":"Radiation Oncology, Azienda di Rilievo Nazionale ad Alta Specializzazione (ARNAS) Civico Hospital","place":["Palermo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Campione","sequence":"additional","affiliation":[{"name":"Clinical Research, Azienda di Rilievo Nazionale ad Alta Specializzazione (ARNAS) Civico Hospital","place":["Palermo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Figlia","sequence":"additional","affiliation":[{"name":"Radiation Oncology, Azienda di Rilievo Nazionale ad Alta Specializzazione (ARNAS) Civico Hospital","place":["Palermo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Spera","sequence":"additional","affiliation":[{"name":"Radiation Oncology, Azienda di Rilievo Nazionale ad Alta Specializzazione (ARNAS) Civico Hospital","place":["Palermo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Cespuglio","sequence":"additional","affiliation":[{"name":"Radiation Oncology, Azienda di Rilievo Nazionale ad Alta Specializzazione (ARNAS) Civico Hospital","place":["Palermo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"D\u2019Alessandro","sequence":"additional","affiliation":[{"name":"Radiation Oncology, Azienda di Rilievo Nazionale ad Alta Specializzazione (ARNAS) Civico Hospital","place":["Palermo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Napoli","sequence":"additional","affiliation":[{"name":"Radiation Oncology, Azienda di Rilievo Nazionale ad Alta Specializzazione (ARNAS) Civico Hospital","place":["Palermo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Azzarello","sequence":"additional","affiliation":[{"name":"Medical Physics, Azienda di Rilievo Nazionale ad Alta Specializzazione (ARNAS) Civico Hospital","place":["Palermo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Verderame","sequence":"additional","affiliation":[{"name":"Medical Oncology, Azienda Ospedali Riuniti (AOOR) Villa Sofia-Cervello","place":["Palermo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Failla","sequence":"additional","affiliation":[{"name":"Pneumology, Azienda di Rilievo Nazionale ad Alta Specializzazione (ARNAS) Civico Hospital","place":["Palermo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livio","family":"Blasi","sequence":"additional","affiliation":[{"name":"Medical Oncology, Azienda di Rilievo Nazionale ad Alta Specializzazione (ARNAS) Civico Hospital","place":["Palermo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Carruba","sequence":"additional","affiliation":[{"name":"Clinical Research, Azienda di Rilievo Nazionale ad Alta Specializzazione (ARNAS) Civico Hospital","place":["Palermo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Ferrera","sequence":"additional","affiliation":[{"name":"Radiation Oncology, Azienda di Rilievo Nazionale ad Alta Specializzazione (ARNAS) Civico Hospital","place":["Palermo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v13.i2.101","article-title":"Single-fraction stereotactic ablative body radiation therapy for primary and metastasic lung tumor: A new paradigm","volume":"13","author":"Fern\u00e1ndez","year":"2022","journal-title":"World J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.05.012","article-title":"Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement","volume":"107","author":"Guckenberger","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.11.051","article-title":"Long-term follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer","volume":"103","author":"Videtic","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2022.05.014","article-title":"Local control with single-fraction lung stereotactic body radiotherapy is not influenced by non-small cell lung cancer histologic subtype","volume":"23","author":"Videtic","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2017.07.001","article-title":"Assessment and management of radiotherapy induced toxicity in older patients","volume":"8","author":"O'Donovan","year":"2017","journal-title":"J Geriatr Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s11547-018-0858-7","article-title":"Hypo-fractionated stereotactic radiation therapy for lung Malignancies by means of helical tomotherapy: Report of feasibility by a single-center experience","volume":"123","author":"Figlia","year":"2018","journal-title":"Radiol Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2019.05.002","article-title":"Prognostic value of two geriatric screening tools in a cohort of older patients with early stage non-small cell lung cancer treated with hypofractionated stereotactic radiotherapy","volume":"11","author":"Cuccia","year":"2020","journal-title":"J Geriatr Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107284","article-title":"Stereotactic body radiotherapy for lung oligo-metastases: Systematic review and International Stereotactic Radiosurgery Society practice guidelines","volume":"182","author":"Mayinger","year":"2023","journal-title":"Lung Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2022.06.014","article-title":"Practical considerations of single-fraction stereotactic ablative radiotherapy to the lung","volume":"170","author":"Kang","year":"2022","journal-title":"Lung Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.19.00480","article-title":"Time-driven, activity-based cost analysis of radiation treatment options for spinal metastases","volume":"16","author":"Boyce-Fappiano","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2023.100584","article-title":"Is single fraction the future of stereotactic body radiation therapy (SBRT)? A critical appraisal of the current literature","volume":"39","author":"Terlizzi","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-020-01627-7","article-title":"Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy","volume":"196","author":"Nicosia","year":"2020","journal-title":"Strahlenther Onkol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109823","article-title":"Local control and toxicity after magnetic resonance imaging (MR)-guided single fraction lung stereotactic ablative radiotherapy","volume":"187","author":"Tekatli","year":"2023","journal-title":"Radiother Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.837577","article-title":"Influence of dexamethasone premedication on acute lung toxicity in lung SBRT","volume":"12","author":"Alite","year":"2022","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.261","article-title":"Stereotactic body radiation therapy for inoperable early stage lung cancer","volume":"303","author":"Timmerman","year":"2010","journal-title":"JAMA"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107822","article-title":"Optimal management of radiation pneumonitis: Findings of an international Delphi consensus study","volume":"192","author":"Voruganti Maddali","year":"2024","journal-title":"Lung Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2017.12.061","article-title":"Management of patients with cardiac implantable electronic devices (CIED) undergoing radiotherapy: A consensus document from Associazione Italiana Aritmologia e Cardiostimolazione (AIAC), Associazione Italiana Radioterapia Oncologica (AIRO), Associazione Italiana Fisica Medica (AIFM)","volume":"255","author":"Zecchin","year":"2018","journal-title":"Int J Cardiol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1933254\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:41:39Z","timestamp":1787114499000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1933254\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":17,"alternative-id":["10.3389\/fonc.2026.1933254"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1933254","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"article-number":"1933254"}}